Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
LumiraDx Limited

LumiraDx Limited (LMDX) Stock Overview

Explore LumiraDx Limited’s financial performance, market position, analyst ratings, and future outlook.

LMDX●NASDAQ
HealthcareMedical - Diagnostics & Research
$0.02
$0.00(0.00%)
U.S. Market opens in 13h 57m

LumiraDx Limited (LMDX)

Meyka AI Score

Z

Key Financials

Market Cap5.1M
P/E Ratio-0.01
EPS (TTM)$-1.08
ROE-15.58%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$0.00

LMDX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of LumiraDx Limited (NASDAQ: LMDX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, LumiraDx Limited's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of LMDX on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.

Key metrics behind LumiraDx Limited's NASDAQ-traded stock include a P/E ratio of -0.01 and a market capitalization of 5.1M. Combined with our AI analysis, these give both institutional and retail investors a clear view of LMDX on the NASDAQ.

Price Performance (NASDAQ: LMDX)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
N/A
6-Month Change
N/A
Year-to-Date (YTD) Change
N/A
1-Year Change
N/A
3-Year Change
-99.35%
5-Year Change
-99.84%
All-Time (Max) Change
-99.84%

Contact Information

https://diagnostics.roche.com/global/en/products/instruments/lumiradx-ins-7781.html
44 11 7284 2535
3 More London Riverside, London, NaN, SE1 2AQ

Company Facts

12,100 Employees
IPO DateMar 19, 2021
CountryGB

Frequently Asked Questions